Research
JPMorgan Upgrades CAMP4 Therapeutics to Overweight From Neutral, Adjusts PT to $9 From $5
CAMP4 Therapeutics (CAMP) has an average rating of buy and mean price target of $8.36, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$CAMP